Related Experiment Video

Updated: Mar 1, 2026

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus
06:14

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

7.5K

Oncolytic Herpes Simplex Viral Therapy: A Stride toward Selective Targeting of Cancer Cells

Dhaval S Sanchala1, Lokesh K Bhatt1, Kedar S Prabhavalkar1

  • 1Department of Pharmacology, Dr. Bhanuben Nanavati College of Pharmacy, Vile Parle (W)Mumbai, India.

Frontiers in Pharmacology
|June 1, 2017
PubMed

Insights

Oncolytic viral therapy, using replication-competent viruses, shows promise for treating cancers. Genetically engineered herpes simplex virus-1 offers enhanced specificity and efficacy in cancer therapeutics.

Area of Science:

  • Oncology
  • Virology
  • Biotechnology

Background:

  • Oncolytic viral therapy utilizes replication-competent viruses to treat malignancies.
  • This approach has demonstrated efficacy in both solid and hematologic cancers.
  • Genetic engineering has significantly improved oncolytic virus specificity and efficacy.

Purpose of the Study:

  • To review oncolytic herpes simplex virus-1 (HSV-1) therapies.
  • To detail genetic alterations in oncolytic HSV-1.
  • To outline developments, limitations, and drawbacks of oncolytic HSV-1 therapy.

Main Methods:

  • Literature review of oncolytic viral therapy research.
  • Focus on herpes simplex virus-1 as a therapeutic vector.
  • Analysis of genetic modifications and their impact on efficacy.

Main Results:

  • Herpes simplex virus-1 offers advantages for oncolytic therapy, including a large genome, tumor infiltration capability, and ease of genetic manipulation.
  • HSV-1 can infect various cancer cells, replicate rapidly, and act as an anti-HSV agent to terminate viral replication.
  • A comprehensive list of genetically altered oncolytic HSV-1 strains is presented.

Conclusions:

  • Oncolytic herpes simplex virus-1 represents a significant advancement in cancer therapeutics.
  • Further research into genetic alterations can optimize oncolytic HSV-1 efficacy.
  • Understanding limitations is crucial for the clinical translation of oncolytic HSV-1 therapies.
Keywords:
cancergenetic armingherpes simplex virusoncolytic viral therapyretargeted oncolytic herpes simplex virus-1

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.3K
Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

10.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.3K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.5K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K